Akebia Therapeutics Ownership | Who Owns Akebia Therapeutics?
Akebia Therapeutics Ownership Summary
Akebia Therapeutics is owned by 46.82% institutional investors, 3.56% insiders, and 49.62% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 7.16% of AKBA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.96% of its assets in Akebia Therapeutics shares.
AKBA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Akebia Therapeutics | 46.82% | 3.56% | 49.62% |
| Sector | Healthcare Stocks | 42.52% | 10.82% | 46.66% |
| Industry | Biotech Stocks | 45.24% | 10.75% | 44.01% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 18.80M | 7.16% | $51.32M |
| Vanguard group | 15.55M | 5.92% | $42.44M |
| Blackrock | 11.64M | 5.68% | $11.87M |
| State street | 11.84M | 4.51% | $32.34M |
| Alerce investment management | 5.75M | 2.73% | $10.92M |
| Geode capital management | 6.18M | 2.36% | $16.89M |
| Morgan stanley | 4.32M | 1.64% | $11.78M |
| Renaissance | 3.95M | 1.51% | $10.79M |
| Ubs group | 3.65M | 1.39% | $9.95M |
| Qube research | 3.21M | 1.22% | $8.75M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Alerce investment management | 5.75M | 19.23% | $10.92M |
| Bioimpact capital | 2.89M | 1.29% | $7.89M |
| Affinity asset advisors | 2.45M | 0.58% | $6.69M |
| Nantahala capital management | 2.00M | 0.19% | $5.46M |
| Orchard capital management | 53.51K | 0.13% | $146.08K |
| Diametric capital, lp | 87.62K | 0.09% | $239.21K |
| Round rock advisors | 143.25K | 0.07% | $426.88K |
| Unified investment management | 18.00K | 0.05% | $49.14K |
| Entrypoint capital | 44.45K | 0.05% | $121.35K |
| Gsa capital partners llp | 182.44K | 0.04% | $498.00K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock | 11.64M | 0.00% | 9.10M |
| State street | 11.84M | 0.00% | 3.85M |
| Ubs group | 3.65M | 0.00% | 3.01M |
| Invesco | 2.40M | 0.00% | 2.02M |
| Citigroup | 1.92M | 0.00% | 1.78M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Aigh capital management | - | - | -2.92M |
| Goldman sachs group | 1.77M | 0.00% | -2.17M |
| Great point partners | - | - | -1.99M |
| Monashee investment management | - | - | -1.50M |
| Eam investors | - | - | -1.45M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Swiss national bank | 509.30K | 0.00% | 509.30K | $1.39M |
| Assenagon asset management | 426.77K | 0.00% | 426.77K | $1.17M |
| Jump financial | 355.84K | 0.01% | 355.84K | $971.45K |
| Voleon capital management lp | 211.77K | 0.01% | 211.77K | $578.12K |
| Freestone grove partners lp | 202.12K | 0.00% | 202.12K | $551.79K |
Sold Out
| Holder | Change |
|---|---|
| Stephens consulting | -6.00 |
| Capital performance advisors llp | -68.00 |
| Hexagon capital partners | -186.00 |
| Laurel wealth advisors | -229.00 |
| Redwood wealth management group | -300.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | 172 | 12.42% | 122,932,544 | 28.32% | 46 | 2.83% | 102 | -3.77% | 34 | 54.55% |
| Jun 30, 2025 | 162 | 8.72% | 108,281,334 | 13.45% | 45 | 2.80% | 111 | 19.35% | 23 | -11.54% |
| Mar 31, 2025 | 150 | 19.05% | 95,500,610 | 40.77% | 40 | 3.90% | 94 | 34.29% | 27 | 22.73% |
| Dec 31, 2024 | 124 | 4.20% | 67,787,367 | 14.05% | 32 | 4.04% | 70 | 18.64% | 22 | -15.38% |
| Sep 30, 2024 | 118 | 9.26% | 59,390,703 | 5.52% | 28 | 3.74% | 59 | 9.26% | 26 | 8.33% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 7.79M | 2.96% | -172.84K |
| Vanguard US Total Market Shares ETF | 5.95M | 2.52% | - |
| iShares Russell 2000 ETF | 6.06M | 2.29% | - |
| SPDR® S&P Biotech ETF | 3.09M | 1.17% | 6.91K |
| Vanguard Institutional Extnd Mkt Idx Tr | 2.59M | 0.99% | -1.16M |
| Fidelity Small Cap Index | 2.50M | 0.94% | 312.83K |
| Foord Global Equity (Lux) A | 1.99M | 0.76% | 1.99M |
| iShares Russell 2000 Value ETF | 1.96M | 0.74% | - |
| Foord Global Equity Class B | 1.83M | 0.70% | 1.83M |
| Nuveen Quant Small Cap Equity R6 | 1.79M | 0.68% | -276.70K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jun 30, 2025 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | Sell | $151.62K |
| Jun 09, 2025 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | $60.15K |
| Jun 04, 2025 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | $47.07K |
| Mar 03, 2025 | Butler John P. | CEO and President | Sell | $84.93K |
| Mar 03, 2025 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | $13.07K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | - | 3 |
| 2025 Q1 | - | 8 |
| 2024 Q2 | - | 2 |
| 2024 Q1 | - | 10 |
| 2023 Q3 | - | 1 |
AKBA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools